Reviewing Nanobiotix (NASDAQ:NBTX) & Chugai Pharmaceutical (OTCMKTS:CHGCY)

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) and Nanobiotix (NASDAQ:NBTX – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.

Insider & Institutional Ownership

0.0% of Chugai Pharmaceutical shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for Chugai Pharmaceutical and Nanobiotix, as provided by MarketBeat.

Nanobiotix has a consensus target price of $37.33, suggesting a potential downside of 0.86%. Given Nanobiotix’s higher probable upside, analysts clearly believe Nanobiotix is more favorable than Chugai Pharmaceutical.

Earnings and Valuation

This table compares Chugai Pharmaceutical and Nanobiotix”s revenue, earnings per share (EPS) and valuation.

Chugai Pharmaceutical has higher revenue and earnings than Nanobiotix.

Profitability

This table compares Chugai Pharmaceutical and Nanobiotix’s net margins, return on equity and return on assets.

Volatility & Risk

Chugai Pharmaceutical has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.

Summary

Chugai Pharmaceutical beats Nanobiotix on 7 of the 13 factors compared between the two stocks.

About Chugai Pharmaceutical

(Get Free Report)

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

About Nanobiotix

(Get Free Report)

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.